Pharming Group N.V. (PHAR) Total Non-Current Liabilities (2019 - 2024)

Pharming (PHAR) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $105.1 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Total Non-Current Liabilities fell 36.71% year-over-year to $105.1 million, compared with a TTM value of $105.1 million through Dec 2024, down 36.71%, and an annual FY2024 reading of $105.1 million, down 36.71% over the prior year.
  • Total Non-Current Liabilities was $105.1 million for Q4 2024 at Pharming, down from $166.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $166.1 million in Q4 2023 and bottomed at $105.1 million in Q4 2024.
  • Average Total Non-Current Liabilities over 5 years is $148.8 million, with a median of $157.6 million recorded in 2021.
  • The sharpest move saw Total Non-Current Liabilities surged 540.98% in 2020, then tumbled 36.71% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $153.6 million in 2020, then grew by 2.64% to $157.6 million in 2021, then increased by 2.43% to $161.5 million in 2022, then grew by 2.88% to $166.1 million in 2023, then tumbled by 36.71% to $105.1 million in 2024.
  • Business Quant data shows Total Non-Current Liabilities for PHAR at $105.1 million in Q4 2024, $166.1 million in Q4 2023, and $161.5 million in Q4 2022.